丁苯酞对血管性痴呆患者认知功能的改善作用  

Improving effect of butylphthalide on cognition in patients with vascular dementia

作　　者：吴娟[1] 付朝晖[1] 杨晋[1] 熊焰[1] 

机构地区：[1]重庆市第三人民医院老年科,400014

出　　处：《重庆医学》2012年第6期571-572,616,共3页Chongqing medicine

摘　　要：目的观察丁苯酞软胶囊治疗轻、中度血管性痴呆(VaD)的临床疗效和安全性。方法 62例轻、中度VaD患者随机分为2组:治疗组31例,给予丁苯酞软胶囊0.2克/次,口服,3次/天;对照组31例,给予维生素E软胶囊0.1克/次,口服,3次/天;两组总疗程为12周。分别于治疗前和治疗后4、8、12周进行认知功能测定,采用简易精神状态检查表(MMSE)、临床痴呆程度量表(CDR)和日常生活能力量表(ADL)作为评价指标。并监测治疗前、后的不良反应以及肌酐、尿素氮、AST、ALT含量的变化。结果对照组治疗前后MMSE、CDR、ADL分数无明显变化(P>0.05),丁苯酞治疗12周后MMSE、CDR、ADL分数分别较治疗前及对照组明显改善(P<0.01)。两组均未发现明显的不良反应。结论丁苯酞可显著改善VaD患者的认知功能,且安全性良好。Objective To observe the efficacy and safety of butylphthalide in the treatment of mild to moderate vascular dementia（VaD）.Methods Sixty-two patients with mild to moderate VaD were randomly divided into 2 groups： the butylphthalide treatment group（n=31） and the control group（n=31）.The participants received either vitamin E capsule（0.1 g,t.i.d.） as control or butylphthalide capsule（0.2 g,t.i.d.） for 12 consecutive weeks.The Mini-Mental State Examination（MMSE）,Clinical Dementia Rating（CDR）,and Activities of Daily Living（ADL） scores were used for the assessment of cognition.The assessments were done prior to treatment,and in 4,8,and 12 weeks after treatment.The adverse effects of butylphthalide were also recorded.Detections were made to observe the changes of creatine（Cr）,blood urea nitrogen（BUN）,glutamic-oxalacetic transminase（GOT） and glutamic-pyruvic transminase（GPT）.Results After 12 weeks of treatment,the MMSE,CDR,and ADL scores were significantly improved in the butylphthalide group（P0.01 for all comparisons）,whereas the control group did not show any improvement（P0.05 for all comparisons）.No serious adverse events were recorded during treatment.Conclusion Butylphthalide can prominently improve the cognitive function of the patients with mild to moderate vascular dementia.Morever,its security and tolerability are good.

关 键 词：痴呆 血管性 丁苯酞 认知功能 

分 类 号：R749.1[医药卫生—神经病学与精神病学]